Here are five things to know:
• The stock has a 1 (strong buy) rating from Zacks Investment
• 12-month consensus target prices is $21
• Earnings per share are expected at $0.33 for the quarter
• K2M traded down 2.38 percent on Monday
• Trading volume is at 142,914
At the beginning of January, Piper Jaffray began coverage on K2M shares and set an “overweight” rating at $25 price target.
More articles on orthopedic devices:
Spine device company stock report: 5 key companies—Feb. 26
Globus Medical acquires device manufacturer—5 key notes
Invuity raises $20M in financing round
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
